Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
2015 ◽
Vol 173
(6)
◽
pp. 1387-1399
◽
2015 ◽
Vol 73
(1)
◽
pp. 37-49
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 597.2-598
2015 ◽
Vol 72
(5)
◽
pp. AB256
◽
2017 ◽
Vol 44
(8)
◽
pp. 873-884
◽
2016 ◽
Vol 74
(5)
◽
pp. AB246
◽
2014 ◽
Vol 70
(5)
◽
pp. AB174
◽
2011 ◽
Vol 165
(3)
◽
pp. 661-668
◽
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 348.2-349
◽